Evidence map›Paper›PMID 33397352›Full record

ArticleCardiovascular diabetology2021

History of lower-limb complications and risk of cancer death in people with type 2 diabetes.

Kamel Mohammedi, Stephen Harrap, Giuseppe Mancia, Michel Marre, Neil Poulter, John Chalmers, Mark Woodward

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Cardiovascular diabetology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 5 countries.

Kamel MohammediDepartment of Endocrinology, Diabetes and Nutrition, Bordeaux University Hospital, Bordeaux, France. km.mmohammedi@gmail.com.ORCID 0000-0001-6139-1197
Stephen HarrapThe University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Giuseppe ManciaThe University of Milan-Bicocca and Istituto Auxologico Italiano, Milan, Italy.
Michel MarreUniversité de Paris, UFR de Médecine, Paris, France.
Neil PoulterThe International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College, London, UK.
John ChalmersThe George Institute for Global Health, Sydney, NSW, Australia.
Mark WoodwardThe George Institute for Global Health, Sydney, NSW, Australia.
Imperial College London · GBInserm · FRJohns Hopkins University · USThe Royal Melbourne Hospital · AUUniversité de Bordeaux · FRUniversity of Milan · ITUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndividuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated this relationship in a large cohort of people with type 2 diabetes.

methodsWe used data from the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) study. The primary outcome was adjudicated cancer death; secondary outcomes were overall and site-specific incident cancers, determined according to the International Classification of Diseases Code (ICD-10). We compared outcomes in individuals with (versus without) a baseline history of lower-limb complications (peripheral artery disease (PAD) or sensory peripheral neuropathy) using Cox regression models.

resultsAmong 11,140 participants (women 42%, mean age 66 years), lower-limb complications were reported at baseline in 4293 (38%) individuals: 2439 (22%) with PAD and 2973 (27%) with peripheral neuropathy. Cancer death occurred in 316 (2.8%) participants during a median of 5.0 (25th-75th percentile, 4.7-5.1) years of follow-up corresponding to 53,550 person-years and an incidence rate of 5.9 (95% CI 5.3-6.6) per 1000 person-years. The risk of cancer death was higher in individuals with (versus without) lower-limb complication [hazard ratio 1.53 (95% CI, 1.21-1.94), p = 0.0004], PAD [1.32 (1.02-1.70), p = 0.03] or neuropathy (1.41 (1.11-1.79), p = 0.004], adjusting for potential confounders and study allocations. PAD, but not neuropathy, was associated with excess risk of incident cancers.

conclusionsPAD and peripheral neuropathy were independently associated with increased 5-year risk of cancer death in individuals with type 2 diabetes. PAD was also associated with increased risk of incident cancers. Our findings provide new evidence on the non-cardiovascular prognostic burden of lower-limb complications in people with type 2 diabetes.

Indexed as

AgedDiabetes Mellitus, Type 2FemaleHumansIncidenceLower ExtremityMaleMiddle AgedNeoplasmsPeripheral Arterial DiseasePeripheral Nervous System DiseasesPrognosisRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTime FactorsCancer deathCancersLower-limb complicationPeripheral arterial diseasePeripheral neuropathyType 2 diabetes

Identifiers

PMID33397352
PMCPMC7784290
OpenAlexW3119477801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.